Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HTO-066
- Development stage
- Preclinical
- Lead developer
- Carna Biosciences
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
HTO-066 is an investigational small-molecule tyrosine kinase 2 (TYK2) agonist initially developed by Carna Biosciences for potential immunology-related indications, and is currently reported to be in preclinical development. As a TYK2 agonist, it is designed to modulate Janus kinase–signal transducer and activator of transcription (JAK–STAT) signaling pathways in immune cells, although detailed target profile, indication focus, and pharmacologic data have not yet been publicly disclosed.
Beyond the preview
Go deeper on HTO-066.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HTO-066.